0001104659-23-105488.txt : 20231002 0001104659-23-105488.hdr.sgml : 20231002 20230929193054 ACCESSION NUMBER: 0001104659-23-105488 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230929 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231002 DATE AS OF CHANGE: 20230929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Envoy Medical, Inc. CENTRAL INDEX KEY: 0001840877 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 861369123 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40133 FILM NUMBER: 231297254 BUSINESS ADDRESS: STREET 1: 4875 WHITE BEAR PARKWAY CITY: WHITE BEAR LAKE STATE: MN ZIP: 55110 BUSINESS PHONE: 651-361-8000 MAIL ADDRESS: STREET 1: 4875 WHITE BEAR PARKWAY CITY: WHITE BEAR LAKE STATE: MN ZIP: 55110 FORMER COMPANY: FORMER CONFORMED NAME: Anzu Special Acquisition Corp I DATE OF NAME CHANGE: 20210115 8-K 1 tm2327268d1_8k.htm FORM 8-K
0001840877 false 0001840877 2023-09-29 2023-09-29 0001840877 dei:FormerAddressMember 2023-09-29 2023-09-29 0001840877 us-gaap:CommonClassAMember 2023-09-29 2023-09-29 0001840877 us-gaap:WarrantMember 2023-09-29 2023-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 29, 2023

 

Envoy Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction

of incorporation)

  

001-40133

(Commission

File Number)

  

86-1369123

(IRS Employer

Identification No.)

 

4875 White Bear Parkway

White Bear Lake, MN

(Address of principal executive offices)

  

55110

(Zip Code)

 

Registrant’s telephone number, including area code: (877) 900-3277

 

Anzu Special Acquisition Corp I

12610 Race Track Road, Suite 250

Tampa, FL 33626

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of each exchange on
which registered
         
Class A Common Stock, par value $0.0001 per share   COCH   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   COCHW   The Nasdaq Stock Market LLC

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On September 29, 2023, Envoy Medical, Inc. (formerly known as Anzu Special Acquisition Corp I) (prior to consummation of the Business Combination (as defined below), “Anzu” and after consummation of the Business Combination, the “Company”) announced that the business combination (the “Business Combination”) between Anzu and Envoy Medical Corporation (“Envoy”), a Minnesota corporation, was completed on September 29, 2023 pursuant to the Business Combination Agreement, dated as of April 17, 2023 (as amended by Amendment No. 1, dated as of May 12, 2023, and Amendment No. 2, dated as of August 31, 2023) by and among Anzu, Envoy and Envoy Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Anzu.

 

The Business Combination was approved by Anzu’s stockholders at a special meeting of stockholders on September 27, 2023 (the “Special Meeting”). The Company expects to commence trading of its Class A common stock and warrants on the Nasdaq Capital Market under the ticker symbols “COCH” and “COCHW,” respectively, on October 2, 2023. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

The information referenced under this Item 7.01 (including Exhibit 99.1) of this Current Report on Form 8-K is being “furnished” under “Item 7.01. Regulation FD Disclosure” and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth under this Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be incorporated by reference into any registration statement, report or other document filed by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01. Other Information.

 

In connection with the Special Meeting, holders of Anzu’s Class A common stock, par value $0.0001 per share (prior to consummation of the Business Combination, “Anzu Class A Common Stock” and after consummation of the Business Combination, “Class A Common Stock”), had the right to elect to redeem all or a portion of their Anzu Class A Common Stock for a per share price calculated in accordance with Amended and Restated Certificate of Incorporation of Anzu, as amended. Holders of approximately 55%, or 2,386,294 shares, of Anzu Class A Common Stock had validly elected to redeem their shares of Anzu Class A Common Stock for a pro rata portion of the trust account maintained by American Stock Transfer and Trust Company holding the proceeds from Anzu’s initial public offering and the sale of private placement warrants (the “Trust Account”), or approximately $10.46 per share and approximately $25.0 million in the aggregate as of September 27, 2023.

 

 

 

 

As previously disclosed, on April 17, 2023, prior to entering into the Business Combination Agreement, Anzu and Envoy entered into an agreement (as amended to date, the “Forward Purchase Agreement”) with Meteora Special Opportunity Fund I, LP (“MSOF”), Meteora Capital Partners, LP (“MCP”), Meteora Select Trading Opportunities Master, LP (“MSTO”) and Meteora Strategic Capital, LLC (“MSC” and, collectively with MSOF, MCP and MSTO, the “Seller”) for an OTC Equity Prepaid Forward Transaction.

 

Anzu consented to Meteora reversing a previously submitted redemption request for 425,606 shares of Anzu Class A Common Stock Meteora submitted for redemption and that these 425,606 shares shall be considered Recycled Shares and eligible for payment to Seller as outlined in the Prepayment section of the Forward Purchase Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms the Forward Purchase Agreement.

 

The Forward Purchase Agreement provides that, no later than the earlier of (a) one business day after the closing of the Business Combination and (b) the date any assets from the Trust Account are disbursed in connection with the Business Combination (the “Prepayment Date”), Seller will be paid directly an aggregate cash amount (the “Prepayment Amount”) equal to the product of (i) the Redemption Price and (ii) the Number of Shares less (y) 50% of the Prepayment Shortfall. On September 29, 2023, the Company paid to Seller separately the Prepayment Amount required under the Forward Purchase Agreement directly from the Trust Account. In addition, the Company transferred 8,512 shares of Class A Common Stock (the “Share Consideration”) to Seller on September 29, 2023.

 

The Company and the Seller agreed to waive the requirement under the Forward Purchase Agreement that the Company must file a registration statement with the SEC registering the resale of the Recycled Shares, the Shortfall Sale Shares, the Share Consideration, the Shortfall Warrants and the Shortfall Warrant Shares (the “FPA Registration Statement”) under the Securities Act within forty-five (45) days following the closing of the Business Combination. From time to time following the closing of the Business Combination, Seller may, at its discretion, sell Shares without a payment obligation to the Company (the “Shortfall Sales”) until such time as the gross proceeds from such Shortfall Sales equal $44,505 (the “Prepayment Shortfall”). At such time that the amount of gross proceeds generated from Shortfall Sales is equal to the Prepayment Shortfall, the Company shall retain an amount equal to 50% of the Prepayment Shortfall on the Prepayment Date and Seller shall pay the remaining 50% of the Prepayment Shortfall on the first OET Date and at such time the Seller may not make any additional Shortfall Sales. The Seller in its sole discretion may request warrants of the Company exercisable for shares of Class A Common Stock in an amount equal to (i) 4,300,000 shares of Class A Common Stock less (ii) the Number of Shares specified in the Pricing Date Notice (“Shortfall Warrants” and the shares of Class A Common Stock underlying the Shortfall Warrants, the “Shortfall Warrant Shares”). The Shortfall Warrants will (i) have an exercise price equal to the Reset Price, (ii) expire on June 30, 2024 and (iii) not provide for cashless exercise or net share settlement.

 

Seller agreed to waive any redemption rights that it had under Anzu’s Amended and Restated Certificate of Incorporation, as amended, with respect to any Recycled Shares in connection with the Business Combination, that would require redemption by Anzu of shares of Anzu Class A Common Stock. Such waiver may have reduced the number of shares of Anzu Class A Common Stock redeemed in connection with the Business Combination, and such reduction could alter the perception of the potential strength of the Business Combination. The Forward Purchase Agreement has been structured, and all activity in connection with such agreement has been undertaken, to comply with the requirements of all tender offer regulations applicable to the Business Combination, including Rule 14e-5 under the Exchange Act.

 

The foregoing description of the Forward Purchase Agreement does not purport to be complete and is qualified in its entirety by references to the full text of the Forward Purchase Agreement, which was filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on April 18, 2023 and incorporated herein by reference.

 

 

 

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit   Description
99.1    Press Release dated September 29, 2023.
104   Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: September 29, 2023

    Envoy Medical, Inc.
     
    By:  /s/ Brent Lucas
      Brent Lucas
Chief Executive Officer

 

 

 

 EX-99.1 2 tm2327268d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

ENVOY MEDICAL CORPORATION AND ANZU SPECIAL ACQUISITION CORP I COMPLETE BUSINESS COMBINATION

 

NASDAQ to list Envoy Medical, developer of an FDA-designated breakthrough device for hearing loss – a novel fully implanted cochlear device

 

White Bear Lake, Minnesota and Tampa, Florida – September 29, 2023 — Anzu Special Acquisition Corp I (“Anzu”) (NASDAQ: “ANZU,” “ANZUU” and “ANZUW”), a special purpose acquisition company, and Envoy Medical Corporation (“Envoy” or “Envoy Medical”), a hearing health company, announced today the completion of their previously announced business combination (“the Business Combination”), resulting in Envoy becoming a publicly listed company. The combined company will operate under the name “Envoy Medical, Inc.” and its Class A common stock and warrants are expected to commence trading on October 2, 2023, on the Nasdaq stock exchange under the new ticker symbols “COCH” and “COCHW”, respectively.

 

“Millions of people have significant hearing loss that may not be adequately treated by hearing aids, a market that we believe will continue to expand as the population ages. We believe that many prospective patients do not seek cochlear implants because they are not satisfied with the currently available options for treatment. In the coming quarters, we anticipate being able to report key milestones in our ongoing clinical trial at the Mayo Clinic and our planned pivotal trial at several of premier cochlear implant centers in the United States,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “We believe that achieving a fully implanted cochlear implant – enabling people to not recharge or change their battery daily or have to worry about external components on their head, among many other potential benefits – will encourage more people with clinically indicated hearing loss to get a cochlear implant and improve their quality of life.”

 

“Anzu believes that Envoy is a leading innovator in an attractive industry with strong growth prospects, competing in a market estimated at over $80 billion in untapped potential opportunity in the United States,” said Whitney Haring-Smith, Chief Executive Officer at Anzu Special Acquisition Corp I. “We believe that Envoy Medical’s Acclaim device may be the first fully implanted cochlear implant commercialized in the United States and is designed to have longer expected battery life than existing competitors.”

 

About Envoy Medical (Nasdaq: COCH)

 

Envoy Medical, headquartered in White Bear Lake, Minnesota, is a Nasdaq listed hearing health company providing innovative medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire.

 

Envoy is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and ultimately quality of life. Learn more at https://www.envoymedical.com.

 

About Anzu Special Acquisition Corp I

 

Anzu is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Anzu intends to focus on high-quality businesses with transformative technologies for industrial applications.

 

 

 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the listing of the combined company’s securities on Nasdaq, as well as any information concerning possible or assumed future operations of Envoy. The forward-looking statements contained in this press release reflect the current views of Anzu and Envoy, as the case may be, about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, Envoy’s performance following the Business Combination; changes in the market price of shares of the combined company’s securities after the Business Combination, which may be affected by factors different from those currently affecting the price of shares of Anzu’s common stock; Envoy’s success in retaining or recruiting, or changes required in, its officers, key employees or directors following the Business Combination; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy’s suppliers, or disruptions in Envoy’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; Envoy’s ability to realize some or all of the anticipated benefits of the Business Combination; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy; a loss of any of Envoy’s key intellectual property rights or failure to adequately protect intellectual property rights; Anzu’s board of directors did not obtain a third-party fairness opinion in determining whether to proceed with the Business Combination; the financial and other interests of Anzu’s board of directors may have influenced its decision to approve the Business Combination; the combined company’s ability to maintain the listing of its securities on Nasdaq following the Business Combination; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in Anzu’s registration statement on Form S-4 (File No. 333-271920) filed by Anzu with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on September 14, 2023 and other documents filed with the SEC from time to time. If any of these risks materialize or Anzu’s or Envoy’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Anzu’s and Envoy’s good faith beliefs, they are not guarantees of future performance. Both Anzu and Envoy disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to both Anzu and Envoy.

 

Contact

 

Matt Kreps

Darrow Associates Investor Relations

(214) 597-8200

mkreps@darrowir.com

 

 

 

 EX-101.SCH 3 coch-20230929.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 coch-20230929_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 coch-20230929_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Addresses, Address Type [Axis] Former Address [Member] Class of Stock [Axis] Common Class A [Member] Warrant [Member] Entity Addresses [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name Units, each consisting of one share of Class A Common Stock and one-third of one redeemable Warrant [Member] EX-101.PRE 6 coch-20230929_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 29, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 29, 2023
Entity File Number 001-40133
Entity Registrant Name Envoy Medical, Inc.
Entity Central Index Key 0001840877
Entity Tax Identification Number 86-1369123
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4875 White Bear Parkway
Entity Address, City or Town White Bear Lake
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55110
City Area Code 877
Local Phone Number 900-3277
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Anzu Special Acquisition Corp I
Common Class A [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol COCH
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
Trading Symbol COCHW
Security Exchange Name NASDAQ
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 12610 Race Track Road
Entity Address, Address Line Two Suite 250
Entity Address, City or Town Tampa
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33626
XML 8 tm2327268d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001840877 2023-09-29 2023-09-29 0001840877 dei:FormerAddressMember 2023-09-29 2023-09-29 0001840877 us-gaap:CommonClassAMember 2023-09-29 2023-09-29 0001840877 us-gaap:WarrantMember 2023-09-29 2023-09-29 iso4217:USD shares iso4217:USD shares 0001840877 false 8-K 2023-09-29 Envoy Medical, Inc. DE 001-40133 86-1369123 4875 White Bear Parkway White Bear Lake MN 55110 877 900-3277 Anzu Special Acquisition Corp I 12610 Race Track Road Suite 250 Tampa FL 33626 false false false false Class A Common Stock, par value $0.0001 per share COCH NASDAQ Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share COCHW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 4 25 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://envoymedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports coch-20230929.xsd coch-20230929_def.xml coch-20230929_lab.xml coch-20230929_pre.xml tm2327268d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2327268d1_8k.htm": { "nsprefix": "COCH", "nsuri": "http://envoymedical.com/20230929", "dts": { "schema": { "local": [ "coch-20230929.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "coch-20230929_def.xml" ] }, "labelLink": { "local": [ "coch-20230929_lab.xml" ] }, "presentationLink": { "local": [ "coch-20230929_pre.xml" ] }, "inline": { "local": [ "tm2327268d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 2, "axisCustom": 0, "memberStandard": 3, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 69, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 32 }, "report": { "R1": { "role": "http://envoymedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2327268d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2327268d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r21" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r13", "r16" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://envoymedical.com/role/Cover" ], "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r15" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r20" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r14", "r15" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r17" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r18" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r15" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r19" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://envoymedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-105488-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-105488-xbrl.zip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end